Government News

The Ministry of Health and Family Welfare has introduced comprehensive regulations for medical devices aimed at aligning the country's regulatory framework with globally accepted standards. This initiative seeks to foster a regulatory ecosystem that promotes growth and innovation in the medical device sector.

CDSCO reported top brands of paracetamol, pantoprazole, amoxicillin and other amongst failed samples reported by CDSCO. These samples are reported to be not of standard quality. Total 59 different brands from well known pharmaceutical industries failed to compile with standard quality.

Top brands like Clavam 625, Mexclav 625, Shelcal, Pan D failed various assays and quality tests, which were collected and tested by different Drugs Testing Laboratories.

Union Minister of Health and Family Welfare & Chemicals and Fertilizers, Shri J.P. Nadda inaugurated the ‘First Policy Makers’ Forum’, here today, which will run until 22nd August 2024. To elevate India's position in the global pharmaceutical sector, the Indian Pharmacopoeia Commission (IPC), in collaboration with the Ministry of Health & Family Welfare and the Ministry of External Affairs, hosted an international delegation of policymakers and drug regulators from 15 countries.

Central Government waives local clinical trials for rare drugs approved in Tier-I countries including USA, UK, Japan, Australia, Canada and EU.

DTAB was apprised that WHO Benchmarking is a process of assessment of National Regulatory Authority (NRA) based on Global Benchmarking Tools (GBT) done by team from WHO. Global Benchmarking of vaccine is the tool followed by WHO that involves the implementation of various regulatory functions at relevant institute of India including CDSCO as NRA.